Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054909 · ClinicalTrials.gov registry record · Phase 2
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03054909: Completed Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03054909 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03054909, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.
Primary Outcome
Incidence of Progression Free Survival after first treatment of ALT-803.
Interventions
- BIOLOGICAL ALT-803 Subcutaneous
- BIOLOGICAL ALT-803 Intraperitoneal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
What the finished NCT03054909 record still lists
NCT03054909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which ALT-803 Subcutaneous is the first listed.
NCT03054909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03054909 about?
NCT03054909 is a clinical study titled "IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer". This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.
What is the current status of trial NCT03054909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2017-09-19. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT03054909?
The interventions under investigation include: ALT-803 Subcutaneous (BIOLOGICAL), ALT-803 Intraperitoneal (BIOLOGICAL).
Who is sponsoring clinical trial NCT03054909?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03054909's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI